IC
BIIB icon

Inverness Counsel’s Biogen BIIB Stock Holding History

Inverness Counsel’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$361K Buy
+1,353
New +$287K 0.02% 142

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Inverness Counsel's BIIB Position: Q3 2022 in Review

Inverness Counsel opened a new position in Biogen (BIIB) in Q3 2022: 1,353 shares worth $361K. The stake represents 0.02% of the portfolio and ranks #142 among its holdings.

987 funds tracked by Wall St. Rank hold BIIB as of Q3 2022.

  • Inverness Counsel held 1,353 shares of Biogen worth $361K as of Q3 2022.
  • Biogen was a new Inverness Counsel position in Q3 2022.
  • Biogen made up 0.02% of Inverness Counsel's portfolio in Q3 2022, its #142 holding.
  • 987 funds tracked by Wall St. Rank held Biogen as of Q3 2022.

Based on Inverness Counsel's 13F filing for Q3 2022, filed 26 Oct 2022.